HPK1 inhibitors(Mitogen-activated protein kinase kinase kinase kinase 1 inhibitors), Lewis-Y antigen inhibitors(Lewis-Y antigen inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors)

+ [2]

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication

Lung Cancer

Inactive Indication-

Originator Organization

Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

Active Organization

Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Clinical Trials associated with Lewis-Y-CAR-T Cells(Guangdong Zhaotai InVivo Biomedicine)

NCT03198052

/ RecruitingPhase 1IIT

CAR-T Targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR for Immunotherapy of Lung Cancer: Phase I Clinical Trial

The third generation of CAR-T cells that target GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR have been constructed respectively and their anti-cancer function has been verified by multiple in vitro and in vivo studies.Clinical studies will be performed to test the anti-cancer function of the these individual or combination of the CAR-T cells for immunotherapy of human cancer patients with GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR
-CAR-T cell immunotherapy on human cancers will firstly be tested.

Start Date01 Jul 2017

Sponsor / Collaborator

Second Affiliated Hospital of Guangzhou Medical University

[+2]

100 Clinical Results associated with Lewis-Y-CAR-T Cells(Guangdong Zhaotai InVivo Biomedicine)

100 Translational Medicine associated with Lewis-Y-CAR-T Cells(Guangdong Zhaotai InVivo Biomedicine)

100 Patents (Medical) associated with Lewis-Y-CAR-T Cells(Guangdong Zhaotai InVivo Biomedicine)

Literatures (Medical) associated with Lewis-Y-CAR-T Cells(Guangdong Zhaotai InVivo Biomedicine)

05 Apr 2023·Science Translational MedicineQ1 · MEDICINE

T _STEM -like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models

Q1 · MEDICINE

Article

Author: Tran, Ben ; Harrison, Aaron ; MacDonald, Sean ; Slaney, Clare ; Wang, Minyu ; Qin, Vicky Mengfei ; Terry, Rachael L ; D'Souza, Criselle ; Darcy, Phillip K ; Neeson, Paul J ; Giuffrida, Lauren ; Thio, Niko ; Tantalo, Daniela ; Kershaw, Michael H ; Desai, Jayesh ; Solomon, Ben ; Harrison, Simon J ; Trapani, Joseph A ; Butler, Jeanne ; Prince, H Miles ; Petrone, Pasquale ; Beavis, Paul A ; Sek, Kevin ; Zhu, Joe Jiang ; Thia, Kevin ; Scott, Andrew M ; Ekert, Paul G ; Nguyen, Thu Ngoc ; Meyran, Deborah

Patients who receive chimeric antigen receptor (CAR)–T cells that are enriched in memory T cells exhibit better disease control as a result of increased expansion and persistence of the CAR-T cells. Human memory T cells include stem-like CD8 + memory T cell progenitors that can become either functional stem-like T (T STEM ) cells or dysfunctional T progenitor exhausted (T PEX ) cells. To that end, we demonstrated that T STEM cells were less abundant in infused CAR-T cell products in a phase 1 clinical trial testing Lewis Y-CAR-T cells (NCT03851146), and the infused CAR-T cells displayed poor persistence in patients. To address this issue, we developed a production protocol to generate T STEM -like CAR-T cells enriched for expression of genes in cell replication pathways. Compared with conventional CAR-T cells, T STEM -like CAR-T cells had enhanced proliferative capacity and increased cytokine secretion after CAR stimulation, including after chronic CAR stimulation in vitro. These responses were dependent on the presence of CD4 + T cells during T STEM -like CAR-T cell production. Adoptive transfer of T STEM -like CAR-T cells induced better control of established tumors and resistance to tumor rechallenge in preclinical models. These more favorable outcomes were associated with increased persistence of T STEM -like CAR-T cells and an increased memory T cell pool. Last, T STEM -like CAR-T cells and anti–programmed cell death protein 1 (PD-1) treatment eradicated established tumors, and this was associated with increased tumor-infiltrating CD8 + CAR + T cells producing interferon-γ. In conclusion, our CAR-T cell protocol generated T STEM -like CAR-T cells with enhanced therapeutic efficacy, resulting in increased proliferative capacity and persistence in vivo.

100 Deals associated with Lewis-Y-CAR-T Cells(Guangdong Zhaotai InVivo Biomedicine)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lung Cancer	Phase 1	China	Guangdong Zhaotai InVivo Biomedicine Co. Ltd.	01 Jul 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Lewis-Y-CAR-T Cells(Guangdong Zhaotai InVivo Biomedicine)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation